Condition: Primary Hypercholesterolaemia · Mixed Dyslipidemia · Sponsor: Daiichi Sankyo
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
This description comes directly from the study's public registry record.
Daiichi Sankyo Contact for Clinical Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| Hospital Mater Dei Contorno | Belo Horizonte, Brazil | Recruiting |
| Hospital Felício Rocho | Belo Horizonte, Brazil | Recruiting |
| Hospital Vera Cruz | Belo Horizonte, Brazil | Recruiting |
| Clinica Procardio Ltda. | Blumenau, Brazil | Recruiting |
| Universidade de Caxias do Sul (UCS) | Caixias Do Sul, Brazil | Recruiting |
| Hospital e Maternidade Angelina Caron | Campina Grande do Sul, Brazil | Recruiting |
| Pontificia Universidade Catolica do Parana-(PUCPR) | Curitiba, Brazil | Recruiting |
| CMEP Centro Multidisciplinar de Ensino Especializado e Pesquisa LTDA | Joinville, Brazil | Recruiting |
| Galileo Medical Research Ltda. | Juiz de Fora, Brazil | Recruiting |
| Hospital Parana - Parana Medical Research Center | Maringá, Brazil | Recruiting |
| Hospital Maternidade e Pronto Socorro Santa Lucia | Pocos de Calda, Brazil | Recruiting |
| Hospital Moinhos de Vento (HMV) | Porto Alegre, Brazil | Recruiting |
+ 11 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.